US calls on radiotherapy firms to join forces in improving safety
This article was originally published in Clinica
The US Food and Drug Administration (FDA) has written to the manufacturers of radiotherapy devices, warning them of the need to take better account of the factors involved in "faulty design and user errors", after receiving almost 1,200 such reports during the last decade.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.